不同年龄女性中大肠杆菌生产双价人乳头瘤病毒疫苗的免疫原性比较
本研究基于III期试验和免疫桥接试验的PPS-I数据,比较了大肠杆菌生产的双价HPV 16/18疫苗在不同年龄女性中的免疫原性。结果显示,几乎所有女性对两种HPV型别均发生血清转化;三剂组中IgG GMC随年龄增长而下降,HPV-16和HPV-18的下降趋势分别在32岁和35岁以上女性中减缓。两剂组中特定抗体在10岁女孩中达到峰值后随年龄下降。
要点
- 该双价HPV疫苗在9-45岁女性中诱导特异性抗体应答。
- 三剂组抗体水平随年龄增长而下降,32/35岁以上下降趋势减缓。
- 两剂组抗体在10岁女孩中峰值最高,后随年龄下降。
核心结论
- 大肠杆菌生产的双价HPV-16/18疫苗在9-45岁女性中诱导特异性抗体应答,抗体水平与年龄呈负相关。
研究设计与样本
- 基于III期试验和免疫桥接试验的免疫原性符合方案集(PPS-I)分析,采集第0个月和最终剂次后一个月(第7个月)血清,用ELISA评估特异性IgG抗体水平。
主要发现
- 合并两项试验PPS-I数据,几乎所有女性对两种HPV型别均发生血清转化。
- 三剂组中,两种HPV型别的IgG GMC随年龄增长而下降,尤其在青少年女孩和年轻女性中。
- HPV-16和HPV-18的下降趋势分别在32岁和35岁以上女性中减缓。
- GMI范围:HPV-16为648至80,HPV-18为218至42。
- 两剂组中,HPV-16和HPV-18特异性抗体在10岁女孩中达到峰值,GMI分别为401和98,之后随年龄下降。
临床怎么用
- 该疫苗在9-45岁女性中均有免疫原性,但年龄较大者抗体水平较低,接种时需考虑年龄因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The safety and efficacy of a recently licensed Escherichia coli (E. coli)-produced bivalent HPV vaccine have been shown. Specific antibody levels are important indicators to evaluate the efficacy of vaccination. Therefore, we compared the immunogenicity of this HPV 16/18 vaccine in females of different ages in this study. METHODS: Immunogenicity of the vaccine was analyzed in the per-protocol sets for immunogenicity (PPS-I) of a phase III trial and an immune-bridging trial. The serum samples were collected at month 0 and one month after the final dose (month 7) to assess the specific IgG antibody levels by ELISA. The seroconversion rates, geometric mean concentration (GMC), and geometric mean increase (GMI) were used to assess the immunogenicity of the test vaccine. The non-linear association of antibody levels with age was estimated via natural cubic splines and the Akaike information criterion was used to assess optimal model. RESULTS: By combining the PPS-I data from the two trials, nearly all of the females seroconverted for both HPV types. In the 3-dose group, the GMC of IgG to both HPV types decreased with increasing age, especially in adolescent girls and young women. For HPV-16 and -18, the declining trend slowed down in women older than 32 and 35 years old, respectively. The GMI ranged from 648 to 80 for HPV-16 and from 218 to 42 for HPV-18. In the 2-dose group, the specific antibodies for HPV-16 and -18 peaked in girls aged 10 years with GMIs of 401 and 98, respectively, and then decreased with age. CONCLUSIONS: The E. coli-produced bivalent HPV-16/18 vaccine induced specific antibody responses in females aged 9-45 years. The antibody levels were inversely associated with age, and the declining trends slowed down in women older than 32 or 35 years for HPV-16 and -18, respectively.
引用
- Chen Q, Zhao H, Yao X, et al. Comparing immunogenicity of the Escherichia coli-produced bivalent human papillomavirus vaccine in females of different ages. Vaccine. 2020. PMID: 32718817. doi:10.1016/j.vaccine.2020.07.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。